Modulation of Serotonin in PAH

Mandy MacLean, University of Glasgow Scotland
PVRI – Pulmonary Vascular Research Institute


Rodatristat Ethyl Publications

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Repeated Once or Twice Daily RVT-1201, a TPH Inhibitor for Treatment of PAH

1 October 2019 European Respiratory Society (ERS) International Congress; Madrid, Spain

Wring S, Rurka J, Crizer KR, Palacios M, Snyder M, Keller L, Evans P, Carpenter D

View Original Publication »

Optimization and Validation of a LC-MS/MS Method for Peripheral Serotonin (5-HT) as a Pharmacodynamic Biomarker of Treatment with Tryptophan Hydroxylase Inhibitors

3 June 2019 67th Conference on Mass Spectrometry and Allied Topics; Atlanta, GA

Crizer KR, Viel F, Thibault FS, Palacios M, Wring S

View Original Publication »

Translational Analysis of RVT-1201 Nonclinical and Clinical Pharmacokinetic and Pharmacodynamic Biomarker Data to Predict Clinical Dose of a Novel TPH Inhibitor for Treatment of Pulmonary Arterial Hypertension

2 February 2019 13th PVRI Annual World Congress on PVD; Barcelona, Spain.

Wring S, Alonso-Galicia M, Crizer KR, Gaukel E, Holman N, Pack T, Palacios M, Rurka J, Carpenter D, Rhodes M.

View Original Publication »

Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension

J Pharmacol Exp Ther. 2017 Feb;360(2):267-279.

Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V.

View Original Publication »


Tryptophan Hydroxylase (TPH) Platform Publications

The Serotonin Hypothesis of PAH – Reviews

Recent advances in pulmonary arterial hypertension

F1000Res. 2018 Jul 24;7.

Wilkins MR, Aman J, Harbaum L, Ulrich A, Wharton J, Rhodes CJ.

View Original Publication »

Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists

Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L967-L983.

Orcholski ME, Yuan K, Rajasingh C, Tsai H1 Shamskhou EA, Dhillon NK, Voelkel NF, Zamanian RT, de Jesus Perez VA

View Original Publication »

Serotonin and pulmonary hypertension–from bench to bedside?

Curr Opin Pharmacol. 2009 Jun;9(3):281-6.

MacLean MR, Dempsie Y.

View Original Publication »


Peripheral Serotonin Modulation with Tph1 Inhibitors

GPCRs in pulmonary arterial hypertension: tipping the balance

Br J Pharmacol. 2018 Aug;175(15):3063-3079.

Iyinikkel J, Murray F.

View Original Publication »

Peripheral Serotonin Synthesis as a New Drug Target

Trends Pharmacol Sci. 2018 Jun;39(6):560-572.

Matthes S, Bader M.

View Original Publication »

Tryptophan Hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension

J Pharmacol Exp Ther. 2017 Feb;360(2):267-279.

Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V.

View Original Publication »


Clinical Data Linking Serotonin to PAH

Appetite-suppressant drugs and the risk of primary pulmonary hypertension

International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 Aug 29;335(9):609-16.

Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B.

View Original Publication »

Increased plasma serotonin in primary pulmonary hypertension

Am J Med. 1995 Sep;99(3):249-54.

Hervé P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L.

View Original Publication »

Preclinical Data Linking Serotonin to PAH

Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression

Am J Respir Crit Care Med. 2013 Jan 1;187(1):78-89.

Ciuclan L, Hussey MJ, Burton V, Good R, Duggan N, Beach S, Jones P, Fox R, Clay I, Bonneau O, Konstantinova I, Pearce A, Rowlands DJ, Jarai G, Westwick J, MacLean MR, Thomas M.

View Original Publication »

Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension

Mol Ther. 2012 Aug;20(8):1516-28.

Morecroft I, White K, Caruso P, Nilsen M, Loughlin L, Alba R, Reynolds PN, Danilov SM, Baker AH, Maclean MR.

View Original Publication »

Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice

Circulation. 2008 Jun 3;117(22):2928-37.

Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L, Nilsen M, Peacock AJ, Harmar A, Bader M, MacLean MR.

View Original Publication »

Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension

Hypertension. 2007 Jan;49(1):232-6.

Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, MacLean MR.

View Original Publication »

Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension

Circ Res. 2006 May 26;98(10):1323-30.

Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, Eddahibi S.

View Original Publication »

Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia

Circulation. 2006 Apr 18;113(15):1857-64.

Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, Hamon M, Adnot S.

View Original Publication »


Patient Engagement Publications

A Framework for Engaging PAH Patients in the Drug Development Process

5 September 2019 Pulmonary Hypertension Association’s Annual PH Professional Network (PHPN) Symposium; Washington, D.C.

Mascherino L.

View Original Publication »